By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

C4 Therapeutics 



Cambridge   Massachusetts    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

C4 Therapeutics is a private biotechnology company developing a new class of drugs based on Targeted Protein Degradation (TPD) to address a broad range of life-threatening and life-impairing diseases. C4T’s Degronimid™ platform uses small molecule drugs to direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. Leveraging this distinctive mechanism provides new opportunities to target traditionally difficult to treat diseases and drug resistance. The wide-ranging potential of the Degronimid approach underpins C4T’s internal drug discovery programs as well as strategic partnerships with leading global pharmaceutical and biotechnology firms.

YEAR FOUNDED:

2015

LEADERSHIP:

Founder and CEO: Marc Cohen

Founders: Ken Anderson, Marc Cohen, Jay Bradner and Nathanael Gray

CSO: Andy Phillips

CAO: Andrea Armstrong

CBO: Tom Needham

JOBS:

Please click here for C4 job opportunities.

FOLLOW C4 THERAPEUTICS:



Key Statistics


Email:
Ownership: Private

Web Site: C4 Therapeutics
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
C4 Therapeutics Announces World-Class Scientific Advisory Board With Expertise In Therapeutics And The Ubiquitin-Proteasome System 11/17/2016 11:44:46 AM
C4 Therapeutics Announces World-Class Scientific Advisory Board With Expertise In Therapeutics And The Ubiquitin-Proteasome System 11/17/2016 10:22:36 AM
C4 Therapeutics Appoints Andrea Armstrong As Chief Administrative Officer 9/22/2016 11:06:42 AM
C4 Therapeutics Appoints Andrew Phillips, Ph.D. As President And Chief Scientific Officer 9/14/2016 10:00:54 AM
C4 Therapeutics Completes Core Scientific Leadership Team To Accelerate The Discovery Of Novel Therapeutics For Targeted Protein Degradation 9/2/2016 9:09:58 AM
C4 Therapeutics Appoints Thomas E. Needham, Jr., MBA As Chief Business Officer 2/17/2016 9:46:00 AM
C4 Therapeutics Appoints Andrew Phillips, Ph.D. As Chief Scientific Officer 2/2/2016 11:42:51 AM
//-->